EligibleTrials

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting · NCT05397639 · Interventional (participants receive a specific treatment) · Lead sponsor: Suven Life Sciences Limited

View the official record on ClinicalTrials.gov →
Alzheimer's disease

Interventions studied

Masupirdine 100 mgMasupirdine 50 mgPlacebo

What this trial is about

This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.

Who can take part

Age range
50 Years to 90 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

44 locations listed across 9 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.